Walleye Capital’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-40,200
Closed -$55.1K – 5726
2024
Q2
$55.1K Sell
40,200
-11,200
-22% -$22.6K ﹤0.01% 4901
2024
Q1
$193K Buy
51,400
+36,200
+238% +$212K ﹤0.01% 4000
2023
Q4
$149K Buy
15,200
+1,400
+10% +$11.4K ﹤0.01% 3841
2023
Q3
$115K Sell
13,800
-16,000
-54% -$183K ﹤0.01% 3877
2023
Q2
$396K Buy
29,800
+6,300
+27% +$76.6K ﹤0.01% 2607
2023
Q1
$272K Buy
+23,500
New +$234K ﹤0.01% 2204

Other funds holding PACB

Walleye Capital's PACB Position: Q3 2026 in Review

Walleye Capital opened a new position in Pacific Biosciences (PACB) in Q3 2026: 409,259 shares worth $970K. The stake represents ﹤0.01% of the portfolio and ranks #3501 among its holdings. This is a return to the name: Walleye Capital previously reported a position in PACB as recently as Q4 2024.

Walleye Capital first reported a position in PACB in Q2 2020 and has held it in 11 quarters since. The position peaked at $3.56M in Q4 2024. 150 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

  • Walleye Capital held 409,259 shares of Pacific Biosciences worth $970K as of Q3 2026.
  • Pacific Biosciences was a new Walleye Capital position in Q3 2026.
  • Pacific Biosciences made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #3501 holding.
  • Walleye Capital first reported a position in Pacific Biosciences in Q2 2020 and has held it in 11 quarters since.
  • Walleye Capital's Pacific Biosciences position peaked at $3.56M in Q4 2024.
  • 150 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.